Abstract
Alloys of titanium, aluminium, vanadium, iron and other metals are traditional materials used in bone tissue surgery. The anchorage of the metallic materials into the surrounding tissue depends of their mechanical and other physical and chemical properties. The integration of metallic material with the surrounding tissue can be markedly improved by appropriate physicochemical surface properties of the material, such as roughness, topography, wettability or presence of certain chemical functional groups. In the present study the first step the surface roughness of samples of pure Ti or Ti6Al4V alloy. In order to influence the adhesion, growth and presence of bone differentiation markers in human osteoblast-like MG 63 cells, we modified as machining or subsequent polishing by diamond paste was performed. In addition, we investigated the interaction of these cells with a newly developed material for construction of bone-anchoring parts of bone implants. These tested materials were treated either with electro-erosion or plasma-spraying with Ti. After the cells seeding (MG63, human osteoblast-like cells of the line MG 63, derived from osteosarcoma of a 13-year-old boy, on different surfaces, the basic parametrs of adhesion and the viability of bone cells were detected, the cell were analysed and cultered for 1–8 days, during 3 different time intervals(expl.1. 4. and 7 day). Cells number, were detected and analyzed in a ViCell XR analyzer. The concentration of molecules participating in cell adhesion, osteoblastic differentiation, was determined semi-quantitatively by the enzyme-linked immunosorbent assay (ELISA) in cell. In addition we performed a reconstruction curve of population density of human osteoblast-like MG 63 cells on day 1, 4 and 8. including calculation of doubling time(DT)in human osteoblast-like MG 63 cells grown on metallic materials with different surface treatments. From the tested surfaces Ti Alloys electroerosion surfaces seem promising materials. They show the best osteointegration parameters in vitro. Nevertheles further in vivo experiments must be performed prior to clinical use.
Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org